Malignant Ascites Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Clover Biopharmaceuticals

Malignant Ascites Pipeline constitutes 5+ key companies continuously working towards developing 5+ Malignant Ascites treatment therapies, analyzes DelveInsight.

Malignant Ascites Overview:

Ascites refers to the accumulation of fluid in the abdominal cavity. When this condition is caused by cancer, it is known as malignant ascites. It is most commonly linked to cancers of the colon, ovaries, breasts, lungs, pancreas, liver, and lymphatic system (lymphoma). Around half of all malignant ascites cases involve peritoneal carcinomatosis, while another 13% are associated with widespread liver metastases that lead to portal hypertension.

Malignant ascites can form through various pathways, such as cancer-related blockage of lymphatic drainage, direct fluid secretion by aggressive tumors, or "functional" cirrhosis in patients with extensive liver involvement that increases portal pressure. This condition is often a sign of advanced disease and carries a poor outlook, with median survival typically ranging from 1 to 4 months.

Request for a detailed insights report on Malignant Ascites pipeline insights @ https://www.delveinsight.com/report-store/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Malignant Ascites Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Malignant Ascites Therapeutics Market.

Key Takeaways from the Malignant Ascites Pipeline Report

DelveInsight's Malignant Ascites pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Malignant Ascites treatment.
Key Malignant Ascites companies such as Clover Biopharmaceuticals, and others are evaluating new drugs for Malignant Ascites to improve the treatment landscape.
Promising Malignant Ascites pipeline therapies in various stages of development include SCB-313, and others.

Recent breakthroughs in the Malignant Ascites Pipeline Segment:

In October 2024, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Korjuny (catumaxomab) for the intraperitoneal treatment of malignant ascites in patients ineligible for further systemic anticancer therapy. Catumaxomab is a bispecific trifunctional antibody targeting EpCAM on tumor cells and CD3 on T cells, facilitating an immune response against EpCAM-expressing tumor cells. ​
In November 2024, Pharmanovia entered into a licensing agreement with Lindis Biotech to commercialize catumaxomab across Europe. This collaboration aims to reintroduce this first-in-class therapy to the market, pending regulatory approval. ​
At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Yuce Bio-B presented interim results from a Phase II trial of M701, a bispecific antibody targeting EpCAM and CD3, for treating malignant ascites caused by advanced epithelial tumors. The study indicated that intraperitoneal infusion of M701 was well-tolerated and showed potential benefits in prolonging puncture-free survival and overall survival. ​

Malignant Ascites Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Malignant Ascites Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Ascites treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Malignant Ascites market.

Download our free sample page report on Malignant Ascites pipeline insights @ https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Malignant Ascites Emerging Drugs

SCB-313: Clover Biopharmaceuticals

Malignant Ascites Companies

More than five notable companies are actively working on developing treatments for malignant ascites. Among them, Clover Biopharmaceuticals has a drug candidate that has reached the most advanced stage so far-Phase I clinical trials.

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Malignant Ascites pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Malignant Ascites Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Malignant Ascites Therapies and Key Companies: Malignant Ascites Clinical Trials and advancements @ https://www.delveinsight.com/report-store/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Malignant Ascites Pipeline Therapeutic Assessment
• Malignant Ascites Assessment by Product Type
• Malignant Ascites By Stage
• Malignant Ascites Assessment by Route of Administration
• Malignant Ascites Assessment by Molecule Type

Download Malignant Ascites Sample report to know in detail about the Malignant Ascites treatment market @ Malignant Ascites Therapeutic Assessment @ https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Malignant Ascites Current Treatment Patterns
4. Malignant Ascites - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Malignant Ascites Late-Stage Products (Phase-III)
7. Malignant Ascites Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Malignant Ascites Discontinued Products
13. Malignant Ascites Product Profiles
14. Malignant Ascites Key Companies
15. Malignant Ascites Key Products
16. Dormant and Discontinued Products
17. Malignant Ascites Unmet Needs
18. Malignant Ascites Future Perspectives
19. Malignant Ascites Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Malignant Ascites Pipeline Reports Offerings: https://www.delveinsight.com/report-store/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.